Analyst Ratings For Antares Pharma (NASDAQ:ATRS)
Today, HC Wainwright reiterated its Buy rating on Antares Pharma (NASDAQ:ATRS).
Some recent analyst ratings include
- 2/15/2018-HC Wainwright Reiterated Rating of Buy.
- 6/23/2017-Chardan Capital initiated coverage with a Buy rating.
- 4/20/2017-Raymond James Financial initiated coverage with a Strong-Buy rating.
- 5/10/2016-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Antares Pharma (NASDAQ:ATRS)
Antares Pharma (NASDAQ:ATRS) has insider ownership of 11.60% and institutional ownership of 34.67%.
- On 10/9/2017 Leonard S Jacob, Director, sold 230,000 with an average share price of $4.05 per share and the total transaction amounting to $931,500.00.
- On 10/3/2017 Thomas J Garrity, Director, sold 30,000 with an average share price of $3.50 per share and the total transaction amounting to $105,000.00.
- On 6/9/2017 Fred M Powell, Insider, bought 130,000 with an average share price of $2.79 per share and the total transaction amounting to $362,700.00.
- On 4/5/2017 Robert F Apple, CEO, sold 40,000 with an average share price of $3.00 per share and the total transaction amounting to $120,000.00.
- On 4/4/2017 Leonard S Jacob, Director, sold 41,762 with an average share price of $2.89 per share and the total transaction amounting to $120,692.18.
- On 4/4/2017 Robert F Apple, CEO, sold 37,000 with an average share price of $3.00 per share and the total transaction amounting to $111,000.00.
- On 4/3/2017 Leonard S Jacob, Director, sold 20,000 with an average share price of $2.88 per share and the total transaction amounting to $57,600.00.
Recent Trading Activity for Antares Pharma (NASDAQ:ATRS)
Shares of Antares Pharma closed the previous trading session at 2.15 up +0.17 8.59% with 2421578 shares trading hands.